Found 16 matching trials
A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
PHASE1This multiple-center, multiple-dose, randomized, double-blind, double-dummy...
Location
Multiple Locations
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
PHASE2This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel...
Location
University of Alabama Hospital
A Study of Bitopertin (RO4917838) in Healthy Male Volunteers
PHASE1This randomized, double-blind, placebo-controlled, dose-escalating study wi...
Location
Multiple Locations
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
PHASE3This multi-center, randomized, double-blind, parallel-group, placebo-contro...
Location
K&S Professional Research Services LLC
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
PHASE3This Phase 3, multi-center, randomized, double blind, parallel-group, place...
Location
Clinical Innovtions Inc
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
PHASE3This randomized, multi-center, double-blind, parallel-group, placebo-contro...
Location
Multiple Locations
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
PHASE3This multi-center, randomized, double blind, parallel-group, placebo-contro...
Location
Multiple Locations
A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers
PHASE1This single-center, randomized, double-blind, four-period crossover study w...
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
PHASE2This randomized, double-blind, placebo- and active-controlled, parallel gro...
Location
Multiple Locations
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
PHASE2This study will determine the efficacy and safety of RO4917838 in patients ...
Location
Multiple Locations